SubQ Infliximab Works for IBD; FDA Clears Complex Colonoscopy Tool; IBS & Diet

Switching from intravenous to subcutaneous infliximab (Remicade) was feasible and well-tolerated among patients with inflammatory bowel disease in clinical remission, according to findings presented at the European Crohn’s and Colitis Organisation (ECCO) Congress.

Also at the ECCO Congress, a 6-month interim analysis of the post-market INSPIRE registry found that the stem cell therapy darvadstrocel continued to be safe and effective in patients with Crohn’s disease and complex perianal fistulas.

Motus GI received FDA clearance to market its PURE-Vu EVS system, an endoscopy system designed to help physicians navigate challenging colonoscopies.

A study in Taiwan found that mothers with occult hepatitis B infection could transmit hepatitis B to their babies, but viremia was cleared after 1 year of vaccination. (Journal of Hepatology)

An Ohio man with primary sclerosing cholangitis became one of the few Black patients in the U.S. to undergo a living donor transplant after an old college roommate offered him part of his liver. (NBC News)

Dietary intervention was the preferred therapy for patients with irritable bowel syndrome. (Clinical Gastroenterology and Hepatology)

Age and nutritional risk contributed to impaired food-related quality of life for young people with Crohn’s disease. (Inflammatory Bowel Diseases)

A randomized trial found fluticasone propionate oral disintegrating tablet (APT-1011) was superior to placebo in improving endoscopic and histological responses, as well as reducing dysphagia for eosinophilic esophagitis. (Clinical Gastroenterology and Hepatology)

R. Todd Stravitz, MD, and his family’s Barbara Brunckhorst Foundation gave $104 million, the largest publicly shared gift in liver disease history to support the new Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University.